Newsroom
FarmaMondo Strategy workshop
Incredible strategy workshop for the global FarmaMondo leadership team in Serpiano, Switzerland. We were blessed with beautiful weather that gave us a [...]
Published On: November 11, 2022FarmaMondo Group and Recordati Rare Diseases sign a new exclusive agreement for three RRD’s rare disease therapies in Hong Kong
Recordati Rare Diseases appoints the FarmaMondo Group as the exclusive commercial partner for its orphan therapies Cosmegen®, Pedea® and Carbaglu® in Hong Kong.
Published On: November 2, 2022FarmaMondo @CPHI Frankfurt
Are you planning to visit the CPHI in Frankfurt? CPHI is the leading trade fair for the pharmaceutical sector. The [...]
Published On: October 28, 2022FarmaMondo @Expopharm in Munich
FarmaMondo @Expopharm in Munich The FarmaMondo’s team took part in the Expopharm congress last week in Munich. After dozens of [...]
Published On: September 15, 2022FarmaMondo Group receives Marketing Authorisation for Qarziba® (dinutuximab beta) for infants with High Risk Neuroblastoma
Qarziba® is an anti-GD2 monoclonal antibody that has shown to improve significantly the event-free and overall survival in children with high-risk neuroblastoma, with an acceptable safety profile.
Published On: July 15, 2022Molteni SPA nominates the FarmaMondo Group as the exclusive partner for its pain and addiction portfolio in Egypt.
Molteni Farmaceutici and FarmaMondo Group signed an exclusive marketing and distribution agreement for certain Molteni’s products of its pain and addiction management portfolio in Egypt.
Published On: June 7, 2022MEA HAYAT FOUNDATION
The Forset Hayat Foundation, the Egyptian charitable organisation supporting children with rare diseases and their families was kick-off in May 2022.
Published On: May 25, 2022FarmaMondo Group and Amryt Pharma sign a new exclusive agreement for two Amryt’s rare disease therapies
Amryt Pharma and FarmaMondo Group signed an exclusive partnership agreement for the orphan disease innovative therapies Myalept®, Lojuxta® in the APAC region.
Published On: May 9, 2022FarmaMondo at EAHP 2022 in Vienna
Come visit us at EAHP in Vienna. From the 23th to the 25th March FarmaMondo will be exhibiting at EAHP [...]
Published On: March 11, 2022FarmaMondo Group and Accendatech USA Inc. partnered to initiate a Managed Access Program for the compassionate supply of ACT-001
FarmaMondo and Accendatech USA Inc. partnered to initiate a Managed Access Program for the compassionate supply of ACT-001 for patients in Hong Kong.
Published On: January 15, 2022FarmaMondo participates in the Arab Health conference in Dubai from 24-27 January 2022
FarmaMondo participates in the Arab Health conference in Dubai from 24-27 January 2022. After a break of 2 years, FarmaMondo [...]
Published On: January 13, 2022FarmaMondo Group and Oasmia sign an agreement to commercialize Paclical® in Russia & CIS
Oasmia Pharmaceutical AB has signed a license agreement with FarmaMondo Group for the commercialization of Paclical® (Apealea®) in Russia and the Commonwealth of Independent States.
Published On: September 17, 2021FarmaMondo Group and Mirum pharmaceuticals enter into an exclusive commercialization agreement for Russia and CIS region
Mirum Pharmaceuticals and FarmaMondo entered into an exclusive distribution and supply agreement appointing the FarmaMondo Group as the exclusive partner to make their innovative product Maralixibat available for Patients in Russia and CIS countries.
Published On: September 10, 2021FarmaMondo Group and Ideogen AG enter into a managed access program agreement to allow Fotolyn, Beleodaq and Marqibo distribution
Ideogen AG and FarmaMondo enter into an exclusive Managed Access Program distribution agreement appointing the FarmaMondo Group as the exclusive [...]
Published On: July 26, 2021FarmaMondo Group and Sarepta Therapeutics announce an agreement to exclusively manage access of eteplirsen and golodirsen
December 2020 – FarmaMondo SA announced an exclusive distribution of eteplirsen and golodirsen for certain patients with Duchenne muscular dystrophy (DMD) in Russia.
Published On: December 27, 2020FarmaMondo Group and Dompe’ farmaceutici: exclusive agreement to distribute oxervate™ in Russia and other CIS countries
November 2020 – Dompé farmaceutici Spa and FarmaMondo entered into an exclusive Managed Access Program distribution agreement appointing the FarmaMondo Group as the exclusive partner
Published On: November 10, 2020FarmaMondo Group to exclusively manage access to Metreleptin (Myalept®) by Amryt Pharma for patients with lipodystrophy in CIS (excluding Russia)
Amryt Pharma (www.amrytpharma.com/) has appointed FarmaMondo, the world’s leader in paid-access to unlicensed medicines, to exclusively manage the access of [...]
Published On: June 1, 2020FarmaMondo Group and EUSA establishes an Emergency Managed Access Program to allow Healthcare Providers to access Siltuximab (Sylvant©) for off label treatment of acute patients of COVID-19
While the world fights through COVID19 pandemic EUSA and Papa Giovani Hospital in Italy had initiated an observational study (SISCO [...]
Published On: April 14, 2020FarmaMondo Group to exclusively Manage Access to Lomitapide (Lojuxta®) for the Swiss and CIS markets
Amryt Pharma (www.amrytpharma.com/) has appointed FarmaMondo, the world’s leader in paid-access to unlicensed medicines, to exclusively manage the access of [...]
Published On: October 2, 2019FarmaMondo Group to exclusively manage access of Qarziba® (Dinutuximab Beta)
FarmaMondo SA, the world’s leader in managing paid-access to unlicensed medicines has been appointed by EUSA Pharma to extend its [...]
Published On: June 1, 2019
